New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2013
06:13 EDTCLSN, KERXStocks with implied volatility movement; KERX CLSN
Stocks with implied volatility movement; Keryx (KERX), Celsion (CLSN) according to iVolatility.
News For KERX;CLSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2015
08:11 EDTCLSNCelsion enrolls first patient in Ovation study for ovarian cancer
Subscribe for More Information
September 25, 2015
07:06 EDTKERXKeryx price target lowered to $18 from $22 at Brean Capital
Subscribe for More Information
September 24, 2015
12:21 EDTKERXCiti says EU approval does not impact Sell on Keryx
Subscribe for More Information
09:05 EDTKERXOn The Fly: Pre-market Movers
HIGHER: Arrowhead Research (ARWR), up 35% after disclosing top-line findings from the Heparc-2001 Phase 2a clinical study of ARC-520, its candidate for the treatment of chronic hepatitis B infection... Conatus Pharmaceuticals (CNAT), up 19% after the company's Phase 2 Portal Hypertension clinical trial of emricasan met its primary endpoints... Keryx Biopharmaceuticals (KERX), up 13% after announcing that the European Commission has approved Fexeric for the control of elevated serum phosphorus levels, or hyperphosphatemia, in adults with chronic kidney disease. LOWER: Caterpillar (CAT), down 5% after announcing restructuring plans, lowering revenue guidance, and having stock initiated with a Sell rating and a $28 price target at Axiom... Twitter (TWTR), down 1.5% after Citi cut estimates below consensus and lowered its price target to $30. DOWN AFTER EARNINGS: Worthington (WOR), down 12.5%... Accenture (ACN), down 3%.
07:06 EDTKERXKeryx wins EU approval for Fexeric treatment of Hyperphosphatemia
Subscribe for More Information
September 21, 2015
09:06 EDTKERXKeryx management to meet with JPMorgan
Meeting to be held in the Mid-Atlantic area on September 24 hosted by JPMorgan.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use